EUVIMEDEUVIMED entdecken
BeobachtungsstudieQuerschnittstudieOpen Access · CC BY 4.0

Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort

Haitham A Mahmoud, W Mohamed Abd Elghany, Mohammed Abdelhakeem, Hasnaa M Ahmed, Nady Semeda, Safaa M Abdelhalim, Alaa M Mostafa, Shaimaa H Zaki, Manar M Sayed, Omar Abdelazim

BMC Gastroenterology · 19.03.2026 · 26 (1)

DOI: 10.1186/s12876-026-04655-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift BMC Gastroenterology, online erschienen am 19.03.2026. Verfasst von Haitham A Mahmoud und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Medicine, Minia University, Minia, Egypt. haythm.abdelhamid@mu.edu.eg. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Uric Acid, Hyperuricemia. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minia University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic steatosis, characterized by excessive triglyceride accumulation within hepatocytes, is the central feature of non-alcoholic fatty liver disease (NAFLD). This spectrum encompasses simple steatosis, non-alcoholic steatohepatitis (NASH), progressive fibrosis, and cirrhosis. NAFLD pathogenesis involves an intricate interplay between nutritional factors, metabolic dysregulation, and genetic predisposition. Evidence suggests hyperuricemia is an independent risk factor for NAFLD, with elevated serum uric acid (SUA) levels associated with increased steatosis severity and fibrosis advancement. This study investigated the association between SUA levels and liver involvement—specifically ultrasound-assessed steatosis grading and elastography-measured liver stiffness—in patients with NAFLD.

Methods

This cross-sectional study enrolled 70 patients aged ≥18 years with ultrasound-diagnosed NAFLD (Group I) and 70 age-, sex-, and residence-matched healthy controls (Group II). Participants were recruited from Minia University Liver Hospital between March 2022 and February 2023. Exclusion criteria included excessive alcohol consumption, viral or autoimmune hepatitis, established cirrhosis, and medications affecting uric acid metabolism. The primary outcome was presence of NAFLD. Evaluations comprised detailed medical history, anthropometric measurements, laboratory testing (including SUA), abdominal ultrasonography for steatosis grading, and two-dimensional shear wave elastography for liver stiffness assessment.

Results

Hyperuricemia prevalence reached 55.7% ( n =39) among NAFLD patients compared to 0% in controls ( p =0.001). Mean SUA concentrations were significantly elevated in the NAFLD group versus controls (5.98 ± 1.9 mg/dL vs. 4.34 ± 0.7 mg/dL, p =0.001). A significant association emerged between hyperuricemia and hepatic steatosis grades ( p =0.032). Multivariate logistic regression identified SUA as independently associated with NAFLD after adjustment for confounders (Adjusted OR 1.45; 95% CI: 1.12–1.88, p =0.005 per 1 mg/dL increment), alongside BMI, waist circumference, triglycerides, and creatinine. Receiver operating characteristic (ROC) analysis demonstrated an optimal 5.3 mg/dL SUA cut-off for NAFLD discrimination (AUC 0.74, 64% sensitivity, 94% specificity, p =0.001).

Conclusion

Elevated SUA levels were consistently associated with NAFLD presence, steatosis severity, and increased liver stiffness. The 5.3 mg/dL threshold warrants further validation. Notable limitations include single-center recruitment potentially limiting generalizability, a cross-sectional design precluding temporal relationship and causality determination, and the possibility of residual confounding from unmeasured variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseUric AcidHyperuricemiaHumansCross-Sectional StudiesFemaleMaleAdultMiddle AgedEgyptElasticity Imaging TechniquesUltrasonographyRisk FactorsCase-Control StudiesPrevalenceSeverity of Illness IndexLiver

Stichwörter der Autor:innen

Hepatic steatosisHyperuricemiaNon-alcoholic fatty liver diseaseSerum uric acid level

Substanzen

Uric Acid

Autor:innen und Institutionen

  • Department of Tropical Medicine, Minia University, Minia, Egypt. haythm.abdelhamid@mu.edu.eg.
  • Department of Tropical Medicine, Minia University, Minia, Egypt.
  • Department of Clinical Pathology, Minia University, Minia, Egypt.
  • Department of Medical Microbiology and Immunology, Minia University, Minia, Egypt.
  • Department of Radiodiagnosis, Minia University, Minia, Egypt.

Förderung

  • Minia University

Zitieren

APA

Mahmoud, H. A., Abd Elghany, W. M., Abdelhakeem, M., Ahmed, H. M., Semeda, N., Abdelhalim, S. M., Mostafa, A. M., Zaki, S. H., Sayed, M. M., & Abdelazim, O. (2026). Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort. BMC Gastroenterology, 26(1). https://doi.org/10.1186/s12876-026-04655-2

Vancouver

Mahmoud HA, Abd Elghany WM, Abdelhakeem M, Ahmed HM, Semeda N, Abdelhalim SM, et al. Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort. BMC Gastroenterology. 2026;26(1). doi:10.1186/s12876-026-04655-2

BibTeX
@article{Mahmoud2026,
  author = {Mahmoud, Haitham A and Abd Elghany, W Mohamed and Abdelhakeem, Mohammed and Ahmed, Hasnaa M and Semeda, Nady and Abdelhalim, Safaa M and Mostafa, Alaa M and Zaki, Shaimaa H and Sayed, Manar M and Abdelazim, Omar},
  title = {Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort},
  journal = {BMC Gastroenterology},
  year = {2026},
  volume = {26},
  number = {1},
  doi = {10.1186/s12876-026-04655-2}
}
Kostenlos starten →